The Closed System Drug Transfer Device Market is expanding as healthcare organizations place greater emphasis on protecting healthcare professionals from hazardous drug exposure while maintaining safe and controlled medication handling. Closed system drug transfer devices (CSTDs) are designed to create a mechanically closed pathway during the preparation and transfer of medications, helping minimize the escape of hazardous drug vapors, aerosols, and droplets while reducing the possibility of external contamination. According to a recent report by Market Research Future, the global market was valued at approximately USD 1.2 billion in 2024 and is projected to reach about USD 3.48 billion by 2035, expanding at a CAGR of 10.17% between 2025 and 2035. Rising cancer incidence and the growing use of cytotoxic medications in chemotherapy are major factors increasing demand for safer drug-transfer solutions. Healthcare institutions are also becoming more focused on occupational safety, contamination prevention, and compliance with medication-handling standards. Membrane-to-membrane systems currently represent the dominant product type, while needleless systems are gaining attention because of their potential to improve handling safety. Key components include vial access devices, syringe safety devices, accessories, and bag or line access devices. Hospitals and clinics represent important end users because chemotherapy and other hazardous-drug preparation activities are frequently performed in these settings. Specialty centers and oncology facilities are also increasing their adoption of CSTD technologies as awareness of occupational exposure risks grows.

Technological advancement is becoming a significant factor shaping the market. Manufacturers are developing improved sealing mechanisms, diaphragm-based technologies, compartmentalized systems, and air-filtration approaches to strengthen containment and simplify drug preparation workflows. The market is segmented by type, component, closing mechanism, technology, end user, and region, reflecting the broad range of solutions available for different healthcare environments. North America currently represents the largest regional market, supported by strong safety awareness, established healthcare infrastructure, and regulatory emphasis on hazardous-drug handling. Asia-Pacific is emerging as a particularly attractive growth region because of expanding healthcare investment, increasing cancer treatment capacity, and growing awareness among healthcare professionals. Companies including Baxter International, B. Braun Melsungen, ICU Medical, Corvida Medical, Equashield, Fresenius Kabi, and McKesson are participating in this competitive landscape. Manufacturers are focusing on product innovation, regulatory compliance, strategic partnerships, and expansion into emerging healthcare markets. High device costs, training requirements, and differences in adoption standards across countries can restrict wider implementation. Nevertheless, increasing occupational safety awareness, rising chemotherapy demand, and continuing innovation are expected to support Market Growth through 2035.